The Korea Atomic Energy Research Institute (KAERI) completed the High-flux Advanced Neutron Application Reactor (HANARO) in 1995 and the radioisotope production facilities(RIPF) in 1997. Many devices and handling tools were developed and applied for the production of radioisotopes. Emphasis on RI production plan was placed on the development of new radiopharmaceuticals, the development of new radiation sources for industrial use and the steady production of selected radioisotopes. The selected items are 166Ho-based pharmaceuticals, fission 99Mo/99mTc generators, and products of 131I and 192Ir and 60Co sources for industrial use. Now KAERI regularly produces radioisotopes (131I, 99mTc, 166Ho, 192Ir, 60Co etc.) and labeled compounds including 99mTc cold kits. Newly developed therapeutic agents are a 166Ho-chitosan complex for liver cancer treatment, a 166Ho patch for skin cancer treatment and devices such as the stent and balloon for the prevention against restenosis of the coronary artery. Feasibility studies on the installation of a 99mTc generator loading facility and on 60Co production for food irradiation were finished. The 192Ir sealed source assembly for NDT has been supplied to domestic users since May 2001. The fission moly process, separation process of non-sealed sources (125I, 33P, 89Sr, 153Sm, 188Re) and fabrication process of sealed sources (169Yb, 75Se) are also under development. For the quality assurance of our final products, we obtained ISO certification in 2000. We are carrying out a feasibility study on a new research reactor for the stable supply of radioisotopes in Korea.